![Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker]()
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential BiomarkerPietanza, M. C.; Kadota, K.; Huberman, K.; Sima, C. S.; Fiore, J. J.; Sumner, D. K.; Travis, W. D.; Heguy, A.; Ginsberg, M. S.; Holodny, A. I.; Chan, T. A.; Rizvi, N. A.; Azzoli, C. G.; Riely, G. J.; Kris, M. G.; Krug, L. M. · Clinical Cancer Research · 2012